Stock fact sheet · data as of

China Pharma Holdings, Inc. (CPHI): fair value, margin of safety and Wheel Score

Healthcare · Drug Manufacturers - Specialty & Generic · China · Speculative / Distressed

Close0.7279
GLS fair value-no model value
Margin of safety-
Wheel Score32No optionscapped: no options
Health3/9Piotroski F-score
Moat2.6/10GLS 10-year score
Market cap$31M330k shares a day
Implied vol.-no listed options
P/E-EPS -1.04
Dividend yieldnone
Beta1.05about the market
Next earnings-no date recorded

Is CPHI undervalued?

China Pharma Holdings, Inc. (CPHI) closed at 0.7279 on 16 Oct 2026. None of the nine GLS valuation models produced a positive value for the stock - the company lost money over the last twelve months, EPS -1.04, it pays no dividend and its debts exceed what its assets would fetch - so there is no GLS average fair value and no margin of safety to report. The quality, option and event numbers below still apply; the Quote page's Wall Street View shows what analysts expect instead.

The nightly engine files CPHI under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.

Nine valuation models for CPHI

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF--Present value of the projected free cash flows, discounted at the cost of capital; no value tonight
Graham Number--The most a defensive investor pays for the earnings and book value per share; no value tonight
Graham Growth--Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight
Lynch--EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight
GLS Growth--EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight
10 Cap--Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight
Payback Time--Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV--Earnings power value: current EPS capitalised at 9% with no growth; no value tonight
Zombie (liquidation)-0.1374-119%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target0.0000-100%Analysts' average 12-month price target. Not in the average

Quality and financial health

Financial health is weak: CPHI passes 3 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 2.6 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.

Returns on capital are thin or negative - ROIC -12.0%, ROE -14.0%, ROA -10.3% - with debt at 0.17 times equity and negative free cash flow.

China Pharma Holdings, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Domestic Pharmaceuticals 100% (quarter Q4 FY2021).

Institutional ownership scores 1/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.

Piotroski F-score3 / 9ROIC-12.0%
GLS Moat2.6 / 10ROE-14.0%
Debt / equity0.17ROA-10.3%
Free-cash-flow yield-0.7%Payout ratio0%
Institutions1 / 10Insiders · Congress5 · 5 / 10

Wheel Score 32: No options

CPHI has no listed options in the nightly snapshot, so there is nothing to sell and the stock cannot be wheeled however good the business; the Wheel Score is capped at 39 and shown as "No options" (32 here). The valuation and quality numbers still apply to owning the shares outright.

Volume runs at 330k shares a day on a market cap of $31M, with a beta of 1.05; the Stability part of the Wheel Score gives that 9 of 20.

PartPointsFrom
Value13 / 250% margin of safety
Health7 / 20Piotroski 3/9
Moat4 / 15moat 2.6/10
Premium0 / 20no option data
Stability9 / 20330k shares/day, $31M cap, beta 1.05

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

No upcoming earnings date is recorded for CPHI in the nightly calendar.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Drug Manufacturers - Specialty & Generic

The 12 companies below are the closest to China Pharma Holdings, Inc. by market cap within the Drug Manufacturers - Specialty & Generic industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
RMTI
Rockwell Medical, Inc.
7.669.84+22%38Weak$31M
HSTI
High Sierra Technologies, Inc.
1.40--28No options$29M
RAPH
Raphael Pharmaceutical Inc.
1.40--21No options$28M
PLNH
Planet 13 Holdings Inc.
0.11000.1486+26%37No options$37M
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
5.24--25No options$25M
TXMD
TherapeuticsMD, Inc.
1.975.39+63%45Weak$23M
AYTU
Aytu BioPharma, Inc.
2.015.29+62%39No options$22M
OPTH
Optimi Health Corp.
3.19--26No options$18M
TLPH
Talphera, Inc.
1.06--32Weak$55M
INCR
InterCure Ltd.
4.656.18+25%45Weak$55M
HYEX
Healthy Extracts Inc.
1.050.6122-72%16No options$15M
ZYBT
Zhengye Biotechnology Holding Limited
1.5310.85+86%36No options$73M

⚖ Compare CPHI with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about CPHI

Is CPHI undervalued right now?

The GLS models could not value CPHI (the company lost money over the last twelve months, EPS -1.04, it pays no dividend and its debts exceed what its assets would fetch), so there is no fair value or margin of safety to compare the price of 0.7279 against.

What is the Wheel Score of CPHI and what does it mean?

CPHI has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".

What is the GLS fair value for CPHI?

None of the nine GLS models produced a positive value for CPHI (the company lost money over the last twelve months, EPS -1.04, it pays no dividend and its debts exceed what its assets would fetch), so there is no GLS fair value tonight.

When does China Pharma Holdings, Inc. report earnings next?

No upcoming earnings date is recorded for CPHI in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.

Does CPHI have listed options, and how liquid are they?

No. The nightly options snapshot found no listed contracts on CPHI, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.